시장보고서
상품코드
1193102

희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별(순환 유리 DNA, 순환 종양 세포, 엑소좀 소포), 제품별, 용도별 - 세계 기회 분석 및 산업 예측(2021-2031년)

Rare Biomarkers Specimen Collection and Stabilization Market By Type (Circulating Cell Free DNA, Circulating Tumor Cells, Exosomes Vesicles), By Product, By Application : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 356 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 희귀 바이오마커 시료 채취 및 안정화 시장은 2021년에 232억 7,004만 달러, 2022년부터 2031년에 걸쳐 CAGR 8.7%를 기록, 2031년에는 541억 4559만 달러에 이를 것으로 예측됨 있습니다.

바이오마커는 생물학적 상태와 상황을 나타내는 측정 가능한 지표입니다. 일반적으로 혈액, 소변, 연부 조직 등의 측정 및 평가에 사용됩니다. 바이오마커는 심박수 및 가속도계 데이터 등 바이탈 파라미터 모니터링에 중점을 둡니다. 희소 바이오마커의 검체 채취에서는, 혈액이나 체내의 다른 부위의 평가에 의해 희소 질환의 원인이 되는 미생물을 특정하고, 이들 검체를 분리 키트나 시약 등을 이용하여 안정화하고, 한층 더 연구를 진행시킨다. 바이오마커에는 분자 바이오마커, 세포 바이오마커, 이미징 바이오마커의 세 가지가 있습니다.

그러나 바이오마커는 결정적인 임상 데이터를 수집하기 전에 치료의 안전성과 효능에 대한 정보를 제공함으로써 임상시험 과정의 부담을 줄일 수 있다. 따라서 조사 중 개입이 참가자에게 해로울 가능성이 밝혀지면 중간에 재평가할 수 있는 기회를 제공할 수 있습니다.

시장 성장의 주요 요인은 만성 질환 및 유전성 질환의 증가, 낭포성 섬유증, 근이영양증, 이분척추 등의 희귀 질환의 발생률 증가, 노년 인구 증가 등이다. 예를 들어, DNA 시퀀싱 및 어레이 기반 기술의 글로벌 리더인 일루미나는 2022년 5월 CE 마크의 체외 진단제 TruSight Oncology(TSO) Comprehensive(EU) 테스트에 컴패니언 진단(CDx) 적응증 추가 하는 것을 발표했습니다. 유럽 전역에서 출시된 이 검사 키트 하나로 여러 종양 유전자와 바이오마커를 평가하여 환자의 암의 특이적인 분자 프로파일을 밝힐 수 있습니다.

게다가 희소질환에 대한 신약 승인 획득을 위한 연구개발 활동 활성화, 희소 바이오마커에 대한 정부의 유리한 상환정책, 최신 의료시설 부문 투자 급증, 정확한 만성질환 진단 수요 증가 등이 시장 성장을 촉진 할 것으로 예상됩니다.

그러나 정부의 규제가 엄격하고 희귀 바이오 마커의 시료 개척이나 표준화와 관련된 비용이 높은 것이 시장 성장을 방해하고 있습니다. 한편, 신흥국의 의료시장, 파마코게노믹스에 있어서의 희소 바이오마커 검체의 용도 확대, 판데믹이나 희소유전병의 리스크 급증은 예측 기간 중의 시장 성장에 유리한 기회를 가져올 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 희귀 바이오마커 시료 채취 및 안정화 시 시장 : 유형별

  • 개요
    • 시장 규모 및 예측
  • 순환형 셀프리 DNA(ccfDNA)
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 순환 종양 세포(CTC)
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 엑소좀?소포
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 희귀 바이오마커 시료 채취 및 안정화 시장 : 제품별

  • 개요
    • 시장 규모 및 예측
  • 분리 키트와 시약
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 채혈관
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 시스템
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 희귀 바이오마커 시료 채취 및 안정화 시장 : 응용 분야별

  • 개요
    • 시장 규모 및 예측
  • 온콜로지
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
    • 온콜로지 희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별
      • 조사 시장 규모·예측 : 지역별
      • 진단약 시장 규모 추이·예측 : 지역별
  • 순환기 질환
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • NIPT
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 트랜스크립트 믹스
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 파마코게노믹스
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 이식거절반응
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 포퓰레이션 스크리닝
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제7장 희귀 바이오마커 시료 채취 및 안정화 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미의 시장 규모·예측 : 유형별
    • 북미 시장 규모·예측 : 제품별
    • 북미의 시장 규모·예측 : 용도별
      • 북미의 온콜로지 희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별
    • 북미의 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽의 시장 규모·예측 : 유형별
    • 유럽 시장 규모·예측 : 제품별
    • 유럽의 시장 규모·예측 : 용도별
      • 유럽 온콜로지 희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 유형별
    • 아시아태평양의 시장 규모·예측 : 제품별
    • 아시아태평양의 시장 규모·예측 : 용도별
      • 아시아태평양의 암 희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 유형별
    • LAMEA의 시장 규모·예측 : 제품별
    • LAMEA의 시장 규모·예측 : 용도별
      • LAMEA 종양 희귀 바이오마커 시료 채취 및 안정화 시장 : 유형별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 프로필

  • Agilent Technologies Inc
  • F Hoffman La Roche
  • Merck Kgaa
  • Bio Rad Laboratories
  • Thermofischer Scientific Inc
  • Qiagen
  • Perkin Elmer
  • Charles River Laboratories International, Inc.
  • Siemens Healthineers
  • Eurofins Scientific, Inc.
ksm 23.03.27

The global rare biomarkers specimen collection and stabilization market was valued at $23,270.04 million in 2021, and is projected to reach $54,145.59 million by 2031, registering a CAGR of 8.7% from 2022 to 2031. Biomarker is a measurable indicator of some biological state or condition. It is usually used in the measurement and evaluation of blood, urine, and soft tissues. Biomarkers focus on monitoring vital parameters such as heart rate and accelerometer data. In rare biomarker specimen collection, the rare disease-causing microorganisms are identified by evaluating blood and other parts of body.These samples are stabilized by using isolation kits, reagents, and other equipment for further study. Molecular biomarkers, cellular biomarkers, and imaging biomarkers are the three different types of biomarkers.

However, a biomarker can lessen the burden of the clinical trial process by providing information about the safety and efficacy of treatments before the collection of definitive clinical data, which provides the opportunity for mid-course re-appraisal, and even interruption if the intervention being investigated is revealed as potentially harmful to participants.

The key factors that drive the growth of market are rise in prevalence of chronic & genetic diseases, increase in incidence of rare diseases such as cystic fibrosis, muscular dystrophy, & spina bifida; and rise in geriatric population. For instance, in May, 2022 Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This single test kit, launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.

Moreover, increased R&D activities for the launch of approved novel drugs on rare diseases, favorable government reimbursement policies for rare biomarkers, surge in investment in the modern healthcare facility sector, and rise in demand for accurate chronic disease diagnosis are anticipated to fuel the market growth.

However, stringent government regulations and high cost associated with the development of rare biomarkers specimen and standardization hamper the market growth. Conversely, emerging healthcare market in developing countries, increase in applications of rare biomarker specimens in pharmacogenomics, and surge in the risk of pandemic & rare genetic diseases are expected to provide lucrative opportunity for the growth of market during the forecast period. 

The rare biomarkers specimen collection and stabilization market is segmented on the basis of type, product, application, and region. By type, the market is categorized into circulating cell free DNA, circulating tumor cells, and exosomes vesicles. By product, the market is classified into isolation kits & reagents, blood collection tubes, and systems. By application, the market is fragmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and other. By application, the oncology segment is further sub-classified into research and diagnostics.Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the rare biomarker's specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The rare biomarkers specimen collection and stabilization market is mainly driven by rise in prevalence of chronic & genetic diseases, increase in the healthcare expenditure, surge in number of approved rare biomarker isolation kits for both clinical and research use are anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region which propels the growth of the market.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, rise in investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring have provided lucrative growth opportunities to players, which is further expected contribute to the growth of the market.

The key players that operate in the rare biomarkers specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc and Siemens AG.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarkers specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarkers specimen collection and stabilization market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the rare biomarkers specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global rare biomarkers specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Circulating Cell Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes Vesicles

By Product

  • Isolation Kits and Reagent
  • Blood Collection Tubes
  • Systems

By Application

  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Others
  • Oncology
    • Type
    • Research
    • Diagnostics
  • Cardiovascular Diseases
  • NIPT

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Agilent Technologies Inc
    • F Hoffman La Roche
    • Merck Kgaa
    • Bio Rad Laboratories
    • Thermofischer Scientific Inc
    • Qiagen
    • Perkin Elmer
    • Charles River Laboratories International, Inc.
    • Siemens Healthineers
    • Eurofins Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Circulating Cell Free DNA (ccfDNA)
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Circulating Tumor Cells (CTCs)
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Exosomes Vesicles
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Isolation Kits and Reagent
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Blood Collection Tubes
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Systems
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Oncology
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
    • 6.2.4 Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
      • 6.2.4.1 Research Market size and forecast, by region
      • 6.2.4.2 Diagnostics Market size and forecast, by region
  • 6.3 Cardiovascular Diseases
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 NIPT
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Transcriptomics
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country
  • 6.6 Pharmacogenomics
    • 6.6.1 Key market trends, growth factors and opportunities
    • 6.6.2 Market size and forecast, by region
    • 6.6.3 Market analysis by country
  • 6.7 Transplant Rejection
    • 6.7.1 Key market trends, growth factors and opportunities
    • 6.7.2 Market size and forecast, by region
    • 6.7.3 Market analysis by country
  • 6.8 Population Screening
    • 6.8.1 Key market trends, growth factors and opportunities
    • 6.8.2 Market size and forecast, by region
    • 6.8.3 Market analysis by country
  • 6.9 Others
    • 6.9.1 Key market trends, growth factors and opportunities
    • 6.9.2 Market size and forecast, by region
    • 6.9.3 Market analysis by country

CHAPTER 7: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Product
    • 7.2.4 North America Market size and forecast, by Application
      • 7.2.4.1 North America Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Product
      • 7.2.5.1.3 Market size and forecast, by Application
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Product
      • 7.2.5.2.3 Market size and forecast, by Application
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Product
      • 7.2.5.3.3 Market size and forecast, by Application
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Product
    • 7.3.4 Europe Market size and forecast, by Application
      • 7.3.4.1 Europe Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Product
      • 7.3.5.1.3 Market size and forecast, by Application
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Product
      • 7.3.5.2.3 Market size and forecast, by Application
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Product
      • 7.3.5.3.3 Market size and forecast, by Application
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Product
      • 7.3.5.4.3 Market size and forecast, by Application
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Product
      • 7.3.5.5.3 Market size and forecast, by Application
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Product
      • 7.3.5.6.3 Market size and forecast, by Application
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Product
    • 7.4.4 Asia-Pacific Market size and forecast, by Application
      • 7.4.4.1 Asia-Pacific Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Product
      • 7.4.5.1.3 Market size and forecast, by Application
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Product
      • 7.4.5.2.3 Market size and forecast, by Application
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Product
      • 7.4.5.3.3 Market size and forecast, by Application
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Product
      • 7.4.5.4.3 Market size and forecast, by Application
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Product
      • 7.4.5.5.3 Market size and forecast, by Application
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Product
      • 7.4.5.6.3 Market size and forecast, by Application
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Product
    • 7.5.4 LAMEA Market size and forecast, by Application
      • 7.5.4.1 LAMEA Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Product
      • 7.5.5.1.3 Market size and forecast, by Application
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Product
      • 7.5.5.2.3 Market size and forecast, by Application
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Product
      • 7.5.5.3.3 Market size and forecast, by Application
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Product
      • 7.5.5.4.3 Market size and forecast, by Application

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Agilent Technologies Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 F Hoffman La Roche
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck Kgaa
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Bio Rad Laboratories
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Thermofischer Scientific Inc
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Qiagen
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Perkin Elmer
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Charles River Laboratories International, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Siemens Healthineers
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Eurofins Scientific, Inc.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제